Abi Carter is timing the partnership with the release of her upcoming album.
American Idol’s 2024 winner is teaming up with Inland Empire Health Plan (IEHP) to promote mental health awareness.1 Abi Carter, an Indio, California, native, is timing the partnership with the release of her first album on November 15. The campaign will be focused on promoting wellness check-ins for young people.
In a press release, IEHP chief executive officer Jarrod McNaughton said, “Besides being a talented musician, Abi has a passion for wellness. Her social media messages about healing, self-care and community, in addition to her strong connection to young audiences, make her the perfect partner to promote these important discussions."
Carter added, “Growing up in Indio as a former member of IEHP, I've seen firsthand the need for greater mental health support, especially for young people. I'm honored to partner with IEHP to spread awareness and help open the conversation around mental wellness."
IEHP is also involved in other charitable activities. In October, the organization announced that it had raised $25,000 for breast cancer research as part of its More Than Pink Walk.2
In a press release issued at the time, IEHP’s chief operating officer Susie White said, “Coming together as an organization to walk reminds me of the family, friends and community who are impacted by breast cancer. I walk for my mom and to remind others that they are not alone in their journey. Together, we can make a lasting impact one step at a time."
Jill Eaton, executive director of the nonprofit's Inland Empire and Nevada region, added, “We are honored to have IEHP, the 2024 Pilar sponsor for the Susan G. Komen Inland Empire MORE THAN PINK walk, [on board]. Together we are making a profound impact in the fight against breast cancer. Supporting individuals in our community who are facing breast cancer is essential to our mission, and we do not do this alone."
"Participation in 'Team IEHP Goes Pink' grows every year, and the generosity of our team never ceases to amaze me," said Rebecca Mayer, director of operations administration for IEHP. "I'm lucky to work for an organization where everyone believes in opening access to optimal care."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.